Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Total Non-Current Liabilities (2017 - 2023)

Denali Therapeutics (DNLI) has disclosed Total Non-Current Liabilities for 7 consecutive years, with $123.0 million as the latest value for Q4 2023.

  • Quarterly Total Non-Current Liabilities fell 70.54% to $123.0 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $123.0 million through Dec 2023, down 70.54% year-over-year, with the annual reading at $123.0 million for FY2023, 70.54% down from the prior year.
  • Total Non-Current Liabilities for Q4 2023 was $123.0 million at Denali Therapeutics, up from $118.1 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $453.0 million in Q4 2020, with the low at $118.1 million in Q3 2023.
  • Average Total Non-Current Liabilities over 5 years is $289.1 million, with a median of $295.0 million recorded in 2020.
  • The sharpest move saw Total Non-Current Liabilities surged 201.41% in 2021, then tumbled 71.61% in 2023.
  • Over 5 years, Total Non-Current Liabilities stood at $158.0 million in 2019, then soared by 186.81% to $453.0 million in 2020, then dropped by 2.55% to $441.5 million in 2021, then fell by 5.45% to $417.4 million in 2022, then crashed by 70.54% to $123.0 million in 2023.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $123.0 million, $118.1 million, and $118.5 million for Q4 2023, Q3 2023, and Q2 2023 respectively.